Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson company Centocor has extended patient enrollment for a phase II trial to evaluate the safety and efficacy of CNTO 1275 for reducing the signs and symptoms of active Crohn's disease.
Subscribe to our email newsletter
CNTO 1275 is a human monoclonal antibody that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), proteins that occur naturally in the immune system and are believed to play a role in the inflammation associated with Crohn’s disease (CD).
Patients who are eligible to participate in the 28-week study will be randomized to one of four treatment groups to receive active drug or placebo. Subjects will be permitted to remain on certain standard CD medications, including steroids and immunomodulators, while participating in the study. Patients will be monitored through 28 weeks with an additional visit at week 54 for a final blood test.
“This study will evaluate the effect of a targeted, human anti-IL-12 monoclonal antibody on Crohn’s disease and its symptoms,” said Dr Dennis Riff, medical director at the Advanced Clinical Research Institute in Anaheim, California. “We look forward to further analysis and evaluation of this therapy as a potential treatment for patients with moderate to severe Crohn’s disease.”